�����������

View information on the companies, licensing and patents that are associated with the commercial development area of the Department of Molecular Virology and Microbiology. 

PHIOGEN Inc.

Founded by Anthony Maresso, Ph.D., in 2023, PHIOGEN Inc. aims to commercialize technology from TAILOR Labs, the personalized phage therapy center at �����������. Based at the Texas Medical Center Innovation Hub, PHIOGEN's team leverages over a decade of phage biology research to create next-generation therapeutics. An exclusive license agreement was signed in 2023.

View website:

Twister Biotechnology Inc.

Formed by Lynn Zechiedrich, Ph.D., to provide services and reagents involving the custom production of DNA minivectors to meet customer specifications. Exclusive license agreement signed 2011.

View website: 

Speratum CR, SA

Formed by Christian Marin-Mueller, Ph.D., a former graduate student in lab of Qizhi “Cathy” Yao, M.D., Ph.D., to develop an miRNA 198-based therapeutic approach to the treatment of pancreatic cancer and other malignancies. Exclusive license agreement signed 2015.

View website: 

ImmuCell

Years of basic research on rotavirus and vaccine candidate virus-like particles by Dr. Mary Estes, Dr. Sue Crawford, Dr. Margaret E. Conner, Dr. Sarah E. Blutt and others leads to a licensing agreement with ImmuCell and theto protect newborn calves from the diarrhea-causing disease.

View website: .

Takeda Pharmaceuticals

Developing a Human Norovirus Vaccine Candidate TAK-214

View website: .